CERT is a blood based diagnostic test that identifies patients who are at risk of heart attack or cardiovascular death. CERT helps to find high-risk patients even if their other clinical parameters such as LDL-C might suggest that they are not at an elevated risk. In Finland, CERT is known as Hertta.
Zora Biosciences Oy announced it has signed a license agreement with Quest Diagnostics, the world leader in diagnostic information services, for Zora's patented ceramide-analysis technology.